How do you get as high as possible? It’s an age-old question that has consumed weed smokers, growers, researchers, scientists, and anyone who’s ever put some kind bud to their lips since humans first discovered the plant.
You’d think that reaching certain degrees of high is a numbers game around buying weed with the highest percentage of THC possible — but it’s not. Scientists reported in a study by Scientific American that, with joints, how high you get is largely defined by how the joint was engineered, from how the weed was broken down and rolled to how the joint burns.
They broke the weed down by different weed particle sizes and hand-rolled the joints to test it. Then, they measured what percentage of cannabinoids reached the end user’s lips and bloodstream. The results alleged that the quality of a joint and getting the most cannabinoids and compounds per puff is about the size of the weed particles after grinding them, the roll quality, and how evenly the final product burns.
The study was headed by Markus Roggen, president and chief science officer of Delic Labs, a cannabis and psilocybin research facility in Vancouver, British Columbia. Roggen and his colleagues questioned whether cannabinoid concentration was the most important factor in determining cannabis’s intoxicating effects and what other factors contribute to an enjoyable experience.
The team of scientists crafted a study where a smoke machine puffed on three pre-rolled paper cones in the same capacity and then measured the volume of cannabis compounds that were delivered. They used a coffee grinder and sieve to grind the cannabis and then hand-rolled the joints. The samples had weed particles that were one millimeter, three millimeters, and five millimeters in diameter.
They made joints from half-gram samples of each and used a “smoke cycle simulator” that inhaled six times for three seconds before exhaling. Filters collected the aerosols at the machine’s 3D-printed mouthpiece, and the researchers used analytical chemistry techniques to measure aerosol levels from puffs taken at the beginning, middle, and end of each joint.
How did we roll the “best” joints possible?
I used this chart to determine what kind of sieve to purchase to get the particle size right. Then I hit Amazon for the cops:
Note: smoking by particle size requires way too much work, and I know you aren’t going to put that effort in. But we did, ya know, for science. However, human trial and error greatly affects variable results in this experiment.
Before testing, I knew the best time to smoke would be in the morning while I was completely sober, so I spaced the samples out between Tuesday, Wednesday, and Thursday mornings. The original study agreed that a human volunteer could not assess this many samples back-to-back with accurate results.
Step 1
I used a red Solo cup and a basic kitchen scale to weigh 0.5-gram samples of LA Cherry Runtz from Flight Path. I rubbed them against the sieves to break down the weed.
During the smoke, I hit each joint six times for three “Mississippis” — the true way to count seconds, just as the study suggested. I jotted my journey over the following three hours to remember and compare the feelings.
Results
Ultimately, I know what you’re wondering: Could I really tell the difference between the highs based on particle size? Unfortunately, no, I could not. I just got high like any other time I’ve smoked a lil’ half-grammer.
When using different sieves for different particle sizes, I did not detect a higher high between a joint rolled with 1mm and 5mm particles. Perhaps some sort of monitor would have suggested differently, but if we’re going off of a human test and human feelings, it simply wasn’t there.
What does this study mean for the future of joints?
As of right now, nothing. Weed companies are not about to start marketing products based on particle size in a world where they are still fighting the THC percentage and indica vs sativa vs hybrid battles. But the information is still nice to know.
Amber Wise, scientific director of the cannabis testing lab Medicine Creek Analytics, said, “Roggen’s data supports the argument that THC percentage matters less than particle size, and pre-roll manufacturers will find this useful.” According to Scientific American, the study concluded that further progress would require addressing variability that persisted in the team’s measurements — even between identically prepared joints.
In future work, Roggen and his colleagues plan to examine how other factors, including humidity, combustion source, and packing density, influence a joint’s architecture and effects. We’ll be around to test those findings, too.
It has been clear the DEA is slow to change for cannabis…but have they done something shady?
It has been clear Anne Milgram, the head of the Drug Enforcement Agency (DEA), is no fan of cannabis and is not pleased with the push to reschedule. Now a lawsuit says DEA acting in bad faith over marijuana. David Heldreth, CEO of psychedelic research firm Panacea Plant Sciences, claims the DEA’s recent actions violate federal law and constitutional principles. Filed in filed in the U.S. District Court for Western Washington, names the Department of Justice, Attorney General Merrick Garland, DEA Administrator Anne Milgram and DEA Judge John J. Mulrooney II as defendants. So what’s going on?
It is no secret, the current President isn’t a fan of cannabis and waited 3 years to fulfill his 2020 promise to help the industry. The timing allowed his administration to pass the decision to the next president. DEA head Milgram has been reluctant about the issue despite recommendation from Health and Human Services, the Food and Drug Administration, the American Medical Association and the American College of Physicians. All of those agencies recommended the change due to clear research showing the medical benefits of cannabis, especially with cancer, chronic pain, PTSD, and inflammation. For the DEA not to follow goes against all precedent.
Heldreth’s alleges legal violations in the DEA’s rulemaking process. He contends the agency failed to consult Native American tribes despite ignificant impact rescheduling marijuana would have on tribal law enforcement and health services. Additionally, Heldreth challenges the constitutionality of the DEA’s Administrative Law Judges, arguing their appointment by the DEA administrator violates Article II of the U.S. Constitution.
Heldreth is the latest in complaints as a Veteran’s organization is claiming they have been blocked from the hearings, despite the Veteran’s administration working with the industry to figure out a pathway for veterans with PTSD.
Milgam has been obstructive to the late in term admisntration’s move, working to stop the process. After the announcement to reschedule, Anne Milgram made the unusual request of a “off the record/no notes meeting” to top deputies summoned in March for what she called the “Marijuana Meeting”. What followed with a request to the Department of Justice (DOJ) which would slow the process if not stop it. The DOJ pushed back on the request.
With millions of patients using medical marijuana, including veterans, plus thousands of mom and pop businesses, Milgram’s actions are murky. Science has changed the direction and it seems the DEA is the only agency standing against the movement.
If you drink alcohol, you can drink, but it has to be out of your body’s system. it is recommended you not have booze 24 hours before donating. Like alcohol, you can donate blood, but you have to let the marijuana move out of your system. Potential donors cannot give if cannabis use impairs their memory or comprehension. The Red Cross does not test blood donations for the presence of tetrahydrocannabinol, or THC, the principle psychoactive component of the cannabis plant. But you should wait 24 hours from the last time you are high.
Donating blood is easy. You go to the nearest location, sign in, show ID, and read some information. You’ll answer questions online or in person, and receive a health check.
The acutional process is easy, a sterile needle is inserted into a vein in your arm, and blood is drawn into a bag. The donation usually takes 8–10 minutes and feels like a quick pinch. Afterwards they providea snack and drink and 10–15 minutes to recovery before resuming your day.
The cannabis industry is concerned about the direction of regulations – and the DEA is still against the plant.
The cannabis industry is very concerned for the future. While many supported the incoming president with hopes for action, things look rough. The Speaker of the House is against legal marijuana, the pro-weed Attorney General nominee seems to be in trouble, and some of the new Senate leadership feel cannabis issues as dead on arrival. And is this giving an indicator to the Drug Enforcement Administration (DEA) to not do anything? It is the DEA against the vast majority of the public about marijuana.
Every poll shows at least 88% of the population is for some form of legal cannabis. Florida had almost 57% of their voting public support full recreation. Almost all major medical organizing including the federal government’s Health and Human Services and the Food and Drug Administration, the American Medical Association and the American College of Physicians have supported rescheduling. Their reason is proven science around it providing clear medical benefits. But the DEA seems to be against it.
Now, the DEA and their Chief Administrative Law Judge John Mulrooney has denied a key group from being part of the hearing. Cannabis has been proven to help with PTSD and the Veterans adminstartion has rearranged its process to allow veterans to seek this option of treatment. The Veterans Action Council (VAC), an organization supporting cannabis access for military veterans, petitioned request “status as an interested party” to give testimony.
This is a follow up from an earlier requested to participate. Despite working with the government, the group was not included on the list of 25 participants released Oct. 31 by DEA Administrator Anne Milgram.
According to a footnote in the order denying the Veteran group a chance to testify, the DEA could allow more participants to testify. But DEA DIrector Milgam has shown no love for cannabis or the industry, and the current list leans heavily into the anti-cannabis group and against the general public.
As reported in early summer, Director Milgram made an unusual request of top deputies summoned in March for the “Marijuana Meeting”: Nobody could take notes. This has made the industry very anxious and hoping for a positive outcome for the thousands of mom and pop businesses.